Caplacizumab

(Cablivi®)

Caplacizumab

Drug updated on 11/14/2023

Dosage FormInjection (intravenous, subcutaneous: 11 mg/vial)
Drug ClassVon Willebrand factor-directed antibody fragment
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.